How many clinical trials are tracked for graft-versus-host disease?

79 trials are tracked, 4 with published results.

graft-versus-host disease Research

Graft-versus-host disease: what the trials found

Established evidence for managing graft-versus-host disease (GVHD) includes several pharmacological interventions. Mycophenolate Mofetil demonstrated a complete response (CR) rate ranging from 44% to 60.3% in clinical trials ⁵. Ibrutinib showed no statistically significant difference in response rates at 48 weeks compared to other cohorts (p=0.5384), nor was there a significant difference in the cumulative incidence of corticosteroid withdrawal ⁶.

Specific treatments for acute GVHD and ocular complications have been evaluated. Prednisone treatment showed that patients receiving secondary therapy for acute GVHD beyond prednisone had significantly lower rates of progression to Grade III-IV acute GVHD (7 vs 13; p=0.009) ⁷. For ocular GVHD, cyclosporine ophthalmic emulsion did not show a statistically significant difference in the number of patients developing the condition compared to placebo (p>0.99) ⁴.

Other established interventions include thiotepa, which showed an estimated event-free survival of 45% to 54% and transplant-related mortality rates of 6% to 13% ³. Etanercept was evaluated with 14 patients achieving complete remission at four weeks, while 29% of patients progressed within 28 days of initiation ⁸.

For the clinician treating this condition

Mycophenolate Mofetil is established with CR rates up to 60.3% ⁵.
Prednisone use was associated with significantly lower progression to Grade III-IV acute GVHD when accompanied by secondary therapy ⁷.
Cyclosporine ophthalmic emulsion showed no significant difference over placebo for preventing ocular GVHD ⁴.

AI synthesis of 8 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.